Clinical Trials Logo

Lymphoma, T-Cell, Peripheral clinical trials

View clinical trials related to Lymphoma, T-Cell, Peripheral.

Filter by:

NCT ID: NCT01155817 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Start date: August 2010
Phase: Phase 1
Study type: Interventional

PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.

NCT ID: NCT01142674 Completed - Clinical trials for Lymphoma, T-Cell, Peripheral

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Start date: September 2006
Phase:
Study type: Observational

The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project). It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes

NCT ID: NCT01129193 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Start date: May 4, 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AR-42 in treating patients with advanced or relapsed multiple myeloma, chronic lymphocytic leukemia, or lymphoma.

NCT ID: NCT01129180 Completed - Clinical trials for Peripheral T-cell Lymphoma

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Start date: May 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractory T-cell lymphoma.

NCT ID: NCT01110733 Completed - Clinical trials for Peripheral T-cell Lymphoma

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

COMPLETE
Start date: February 2010
Phase:
Study type: Observational

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

NCT ID: NCT01110135 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim together for peripheral stem cell mobilization works in treating patients with refractory or recurrent lymphoma or multiple myeloma. Giving chemotherapy, such as bendamustine hydrochloride, etoposide, and dexamethasone, before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim, and certain chemotherapy drugs helps stem cells move from the bone marrow to the blood so they can be collected and stored

NCT ID: NCT01075321 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Start date: January 10, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma.

NCT ID: NCT00970385 Completed - Clinical trials for Peripheral T Cell Lymphoma

Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma

LTP
Start date: January 1995
Phase: Phase 3
Study type: Interventional

This is a multicenter randomized trial evaluating induction treatment with VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T cell lymphoma.

NCT ID: NCT00963274 Completed - Lymphoma Clinical Trials

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: April 26, 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of giving bortezomib and romidepsin together in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent B-cell lymphoma, peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Bortezomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00930605 Completed - Clinical trials for Peripheral T-cell Lymphoma

The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)

C+CHOP/ESHAP
Start date: January 2005
Phase: Phase 2
Study type: Interventional

1. Primary Research Question What are the rates of complete response (CR), partial response (PR), progression free survival (PFS) and overall survival (OS) in adult patients newly diagnosed with Peripheral T-Cell Lymphoma (PTCL) who are treated with alemtuzumab given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and ESHAP (etoposide, methylprednisolone, cisplatin, cytosine arabinoside) administered as an up-front treatment? 2. Secondary Research Question What is the incidence of life-threatening toxicities (grade 3 and 4, according to WHO criteria, Appendix A) in the patients?